Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 12/20 | 0.53 |
| ▸ | CDK9 | P50750 | 10/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.53 |
| ▸ | CDK2 | P24941 | 9/20 | 0.53 |
| ▸ | CCNK | O75909 | 8/20 | 0.53 |
| ▸ | CDK12 | Q9NYV4 | 8/20 | 0.53 |
| ▸ | CDK7 | P50613 | 7/20 | 0.53 |
| ▸ | CCNH | P51946 | 6/20 | 0.53 |
| ▸ | MNAT1 | P51948 | 5/20 | 0.53 |
| ▸ | PRKCI | P41743 | 3/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234588 | 1.00 | CCNT1 (0.53) | CCNT1CDK9CCNE1CDK2CCNK | |
| SCHEMBL2231936 | 0.89 | CDK2 (0.44) | CCNT1CDK9CCNE1CDK2CCNK | |
| SCHEMBL2232768 | 0.89 | CCNT1 (0.44) | CCNT1CDK9CCNE1CDK2CCNK | |
| SCHEMBL2232771 | 0.89 | CCNT1 (0.44) | CCNT1CDK9CCNE1CDK2CCNK | |
| SCHEMBL2346892 | 0.86 | CCNT1 (0.70) | CCNT1CDK9CCNE1CDK2CCNK | |
| SCHEMBL2346895 | 0.86 | CCNT1 (0.70) | CCNT1CDK9CCNE1CDK2CCNK | |
| SCHEMBL2231095 | 0.82 | CDK7 (0.48) | CCNT1CDK9CCNE1CDK2CCNK | |
| SCHEMBL2231093 | 0.82 | CDK7 (0.48) | CCNT1CDK9CCNE1CDK2CCNK | |
| SCHEMBL15167373 | 0.79 | JAK2 (0.47) | — | |
| SCHEMBL2349185 | 0.79 | JAK2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| EP-2360158-A1 | Pyrazole derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | CCNT1 587/4885CDK9 192/4885CCNE1 2016/4885 |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | CCNT1 1120/4885CDK9 45/4885CCNE1 1161/4885 |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | CCNT1 1120/4885CDK9 45/4885CCNE1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.